UAB offers two national clinical trials with customized treatment for lung cancer patients.
Macrophage cells require agility to scavenge and digest dead cells and prevent an immune response to self. In lupus, the macrophages lose that agility.
A series of fascinating studies at Harvard University showed that many people respond positively to placebo pills — even when they are told that the pills don't have any active ingredients. Now researchers at UAB have partnered with a Harvard scientist to test these "open-label" placebos for the first time in cancer survivors.
Deadlines for abstracts are set for early fall and are open to graduate students, postdoctoral fellows, clinical fellows and residents.
A UAB researcher suggests that autoimmune disease therapy may be an effective treatment for idiopathic pulmonary fibrosis.
HIV/AIDS is the leading cause of death worldwide for women ages 15-44 years, and UAB serves as a site for the latest study by the Microbicide Trials Network, which has previously studied this new approach with positive results in other female age groups.
UAB presented an observational study at this week’s annual American Society of Clinical Oncology meeting in Chicago that indicates a more rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program.
David Pollock, Ph.D., professor in the Division of Nephrology, recently visited Cuba with a delegation from the American Physiological Society to sign a historic agreement for research collaboration with leaders of the Cuban Society of Physiological Sciences.
Nicholas Van Wagoner, M.D., Ph.D. recently joined the Department of Medical Student Services as assistant dean for students.
UAB presented an observational study at this week’s annual American Society of Clinical Oncology meeting in Chicago that indicates a more rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program.
Page 1 of 15